Dementia Discovery Fund
Venture capitalLondon · Seed–Series A · 80 people tracked
Find your way into Dementia Discovery Fund
646 people in our graph share verified history with the Dementia Discovery Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
SV Health Investors is a healthcare-focused investment firm managing multiple funds across therapeutics, biotech, healthcare growth and medtech, including the Dementia Discovery Fund.
Source: firm website, verified Jul 30, 2026.
Team · 80 people
from the firm's website
What they invest in
from 19 of 19 portfolio companiesBiotech ×16Healthtech ×11Deep Tech ×6Medical Devices ×6Digital Health ×4AI & Machine Learning ×3Data & Infrastructure ×2Longevity ×2
HQs:United States×10United Kingdom×3Australia×1
Investments · 19 tracked
founders shown can be your intro pathBy year:2025 · 22023 · 52022 · 12021 · 19 dated
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsForesite CapitalGV (Google Ventures)SV Life SciencesDementia DiscoveryLightstone VenturesSV Health Investors+2 more
NeuLogiq is a research platform for clinical trials that integrates tablet-based cognitive assessments, EEG monitoring, and real-world behavioral data to measure brain function changes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBelfast, GB
Brian Murphy(Co-Founder & CSO)inTina(CEO)
Co-investorsClarendon Fund Managers Ltd.LifeArc Ventures
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets.
BiotechHealthtech
Jan Thirkettle(CEO Director)in
Co-investorsEpidarex CapitalOno Venture Investment, Inc.SV Health Investors
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)Michael Ross(Director)
Board seatNeil Weir· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaQiming HealthcareQiming Venture Partners USA
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioRA CapitalLightstone VenturesOno Venture Investment, Inc.British Business Bank+2 more
Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.
BiotechCambridge, GB
Louise Modis(Chief Executive Officer)inMartin Pass(Chief Development Officer)inGiles Brown(Executive VP Drug Discovery)in
Co-investorsAdvent Life SciencesNovartis Venture FundSV Health InvestorsEuropean Investment FundForbionGilde Healthcare+1 more
Endlyz develops small-molecule disease-modifying therapeutics targeting the ATP13A2 and ATP10B lysosomal transporters to restore endo-lysosomal function and counter neurodegeneration.
BiotechDeep TechBoston, US
Joanna Wolak(Executive Officer, Director)inJonathan Behr(Director)John Gustofson(Director)Damian Crowther(Director)Zaven Kaprielian(Executive Officer, Director)
BoardLaurence Barker(Director)
Co-investorsOxford Science Enterprises
LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.
BiotechDeep TechCambridge, GB
David Reynolds(Co-founder & CEO)inCaroline Benn(Co-founder & CSO)in
Co-investorsNovartis Venture FundSV Health InvestorsForbion
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalSofinnova PartnersMission Bay Capital
BiotechJackson, US
Irene Griswold-Prenner(Executive Officer, Director)
BoardZach Hall(Director)Ephraim Heller(Director)William McDowell(Director)Regis Kelly(Director)
Co-investorsSV Health InvestorsSofinnova Partners
NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's.
BiotechHealthtechLongevity
Neil Miller(CEO)inRichard Rutter(CSO)inGrant Hawthorne(COO)inClaus Sundgreen(Chief Medical Officer)inPaul Thompson(CDO)in
BoardJonathan Savidge(Independent Non Executive Chair)
Co-investorsCriteria Bio VenturesNovartis Venture FundSV Health InvestorsBritish Business BankM Ventures
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsDroia VenturesMC Healthcare VenturesMission BiocapitalMitsui Global InvestmentSanofi VenturesSV Health Investors+6 more
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+1 more
Sudo Biosciences develops small molecule therapeutics for neurological and immune-mediated inflammatory conditions.
BiotechHealthtechMedical DevicesMenlo Park, US
Jim Bristol(Director)Daniel Estes(Director)Scott Byrd(Executive Officer, Director)
Co-investorsFrazier Life SciencesMonograph Capital PartnersSanofi VenturesSV Health InvestorsTPG
SV Health Investors is a global private equity and venture capital investment platform specializing in healthcare across biotechnology, medical devices, and healthcare growth equity.
BiotechHealthtechMedical DevicesBoston, US
Co-investorsDementia Discovery
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)Laia Crespo-Martin(Director)
Co-investorsMRL Ventures FundSanofi VenturesSV Health InvestorsAngelini VenturesMitsui Global InvestmentApollo Health Ventures+1 more
Violet Labs builds software tools for engineers designing and building physical products across industries including aerospace, defense, robotics, and energy.
Data & InfrastructureDeveloper ToolsEnterprise SoftwareHardware
Lucy Hoag(Founder)in
Co-investorsFelicis VenturesMaC Venture CapitalV1 VCHopelabNorthwell HoldingsOno Venture Investment, Inc.+2 more
Violet provides free, personalised support for Australian families navigating end-of-life care, combining human connection and technology to offer practical guidance, emotional support, and tools for important conversations.
Digital HealthFintechHealthtechImpact & Social GoodMental HealthHaymarket, AU
BoardKate Carnell(Chairperson)
Co-investorsTechstarsHopelabNorthwell HoldingsOno Venture Investment, Inc.The Venture CollectiveUTEC
Violet provides healthcare organizations with data analytics and tools to measure and improve their ability to deliver person-centered care that considers patients' individual preferences, identities, and experiences.
Data & InfrastructureDigital HealthHealthtechNew York City, US
Gaurang Choksi(CEO and Founder)inScott Zaloom(Head of Operations)inDr. Kay Nikiforova(Head of Clinical & Research)inEliot Kristan(Head of Engineering)in
Co-investorsSeae VenturesSemperVirens Venture CapitalThe Venture CollectiveW Health Ventures Gp LlcHopelabNorthwell Holdings+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Alchemab Therapeutics · healthcaretoday.com · Jul 22, 2026
Therini Bio · ophthalmologytimes.com · May 21, 2026
EndLyz Therapeutics · parkinsons.org.uk · Apr 27, 2026
Quralis · nasdaqprivatemarket.com · Apr 3, 2026
Frequently asked questions
- What stage does Dementia Discovery Fund invest at?
- Dementia Discovery Fund invests at the Seed, Series A stages.
- What sectors does Dementia Discovery Fund focus on?
- Dementia Discovery Fund focuses on Biotech, Digital Health, Healthtech, IoT, Medical Devices.
- Where is Dementia Discovery Fund located?
- Dementia Discovery Fund is headquartered in London, GB.
- Does Dementia Discovery Fund lead rounds?
- Dementia Discovery Fund has led 6 of the 11 rounds where its role is on record.
- Who does Dementia Discovery Fund co-invest with?
- Dementia Discovery Fund most often shares deals with Dementia Discovery, Lightstone Ventures, Ono Venture Investment, Inc., among 4 tracked co-investors.
Similar investors
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Elm Street Ventures is a seed and early-stage venture fund in New Haven, Connecticut that primarily backs companies with a Yale connection, especially technology developed at and licensed from Yale.
Ambix is a healthcare-focused investment firm that provides funding, strategy, and hands-on support to companies developing medical tools and devices, biochemistry-based technologies, digital health applications, and other novel healthcare solutions. It invests across all stages and also builds companies itself.
MDI Ventures is the corporate venture capital arm of Telkom Indonesia, investing in and building synergies between technology startups and Indonesian enterprises. It manages a multi-fund platform (including Centauri Fund, Arise, and sector-specific funds) with a portfolio of 80+ companies.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.